On November 10, 2025, the U.S. Food and Drug Administration (FDA) announced that it will remove the black box warning from most menopausal hormone therapy (MHT) products. A black box warning—the FDA’s most prominent safety alert—had long appeared on estrogen-alone and estrogen-plus-progestogen therapies used to relieve symptoms such as hot flashes, night sweats and vaginal dryness.
The change marks a major shift in women’s health policy and affects millions of women. The FDA concluded that the warning no longer reflects modern evidence about the benefits and risks of hormone therapy.
The Study That Sparked Two Decades of Fear
In 2002, results from the Women’s Health Initiative (WHI) transformed the way doctors viewed hormone therapy. The WHI included two large randomized trials comparing hormone therapy with placebo in postmenopausal women.
- Combined therapy: 16,608 women with an intact uterus (average age 63) were randomly assigned to conjugated equine estrogen plus medroxyprogesterone acetate or placebo. The study results found that those receiving hormones had higher risks of breast cancer, heart disease, stroke, dementia and blood clots, but lower risks of fractures and colorectal cancer.
- Estrogen-alone therapy: 10,739 women who had undergone hysterectomy received estrogen alone or placebo. The study reported tht estrogen alone did not increase breast-cancer or heart-disease risk but was associated with more strokes and blood clots and fewer fractures.
When the first results were released, headlines were dramatic. Media coverage portrayed hormone therapy as dangerous, prompting millions of women to stop treatment abruptly. Within a few years, prescriptions had dropped by about 60-70 percent and the FDA required a black-box warning on all hormone therapy products.
Reevaluating the Data: What We Know Now
The WHI findings were generalized to all women, even though most participants were in their early 60s. This is well past the age when most women begin therapy. Follow-up analyses over the next two decades painted a more nuanced picture.
Women who started hormone therapy within 10 years of menopause or before age 60 had lower rates of coronary heart disease and overall mortality than those on placebo. This became known as the “timing hypothesis.”
Formulation and route also matter. Transdermal estrogen which is delivered through patches, gels, or sprays appears to carry a lower risk of blood clots and stroke than oral estrogen. Breast-cancer risk depends on the combination and duration of use: estrogen + progestin slightly raises risk after several years, while estrogen alone (for women without a uterus) may reduce it.
The dementia signal also proved age-specific, appearing mainly in women who began therapy after age 65.
Hormone Therapy Can Be Safe and Effective for the Right Patient
Removing the black box warning does not signal a blanket endorsement of hormone therapy. Instead, it acknowledges the importance of a more nuanced, individualized approach to assessing risk and benefit.
For many women in their 40s and 50s, particularly those early in menopause, hormone therapy remains an effective treatment for severe vasomotor symptoms like hot flashes and night sweats. Used appropriately, it can improve sleep, energy and overall quality of life.
Preferred approaches include transdermal or low-dose oral estrogen, combined with a progestogen for women with a uterus. Local vaginal estrogen effectively treats dryness and urinary discomfort with minimal systemic absorption.
According to a 2022 position statement by North American Menopause Society, for most healthy women under 60 or within 10 years of menopause, the benefits outweigh the risks.
Key Safety Warnings Remain
The FDA is maintaining one black box warning: estrogen-alone therapy without a progestogen increases the risk of endometrial cancer in women with an intact uterus. That long-established risk remains unchanged.
Other precautions also still apply. Women with a history of breast cancer, stroke, clotting disorders or active liver disease should generally avoid systemic hormone therapy. For these patients, non-hormonal options such as selective serotonin reuptake inhibitors (SSRIs), gabapentin or lifestyle measures may offer relief.
A Shift Toward Personalized Medicine
The FDA’s decision reflects a broader evolution in medicine: recognizing that population averages do not always dictate individual outcomes. The “average” WHI participant was 63, well past menopause. Yet the findings shaped care for women decades younger. For a 51-year-old just entering menopause, the balance of risks and benefits is different.
Personalized menopause care means evaluating not only whether to start hormone therapy but also when to start, which formulation to use, and how to deliver it. Transdermal estrogen lowers clotting risk compared with pills and ultra-low-dose regimens may minimize side effects while maintaining relief.
The new FDA labeling gives clinicians greater flexibility to tailor therapy. It also may encourage renewed research into optimal timing, dosage and duration to maximize both safety and efficacy.
What Women Can Do Now
For many women, menopause brings symptoms that profoundly affect daily life: sleepless nights, hot flashes, mood changes and feelings of not being yourself. The FDA’s decision opens the door for a fresh look at options once dismissed as too risky.
Women should start by talking with a trusted clinician who can review one’s health history and goals. Beginning therapy earlier in menopause and using transdermal patches rather than pills may lower risks while easing symptoms. The aim is to use the smallest effective dose and revisit the plan regularly.
Routine screenings including mammograms, cholesterol checks and blood-pressure monitoring are essential. And while compounded “bio-identical” hormones are often marketed as natural, FDA-approved formulations are more reliable and tightly regulated for safety and consistency.
Ultimately, menopause is not a disease. But it can be a challenging transition. With new guidance grounded in science rather than fear, women and clinicians can now engage in open, informed conversations about how to navigate it with confidence and compassion.
